Literature DB >> 8156917

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

R V Campos1, Y C Lee, D J Drucker.   

Abstract

Proglucagon mRNA transcripts are transcribed in the pancreas, bowel, and brain, after which posttranslational processing results in the liberation of a different profile of biologically active peptides in each tissue. The receptors for two of these peptides, glucagon and glucagon-like peptide-1 (GLP-1), have recently been identified, but only limited information is available concerning the tissue- and age-specific distribution of these receptors in vivo. We have investigated the expression of these receptors in the mouse using a combination of Northern blot analysis and reverse transcription-polymerase chain reaction. DNA sequence analysis of a partial mouse glucagon receptor cDNA demonstrated a high degree of sequence conservation across rodent species. Glucagon receptor mRNA transcripts were detectable by Northern blotting in poly(A)+ RNA from liver and kidney. Reverse transcription-polymerase chain reaction also detected glucagon receptor mRNA transcripts in both fetal and adult pancreas and lung, jejunum, and ileum, but not in the large intestine. In contrast, mRNA transcripts for the GLP-1 receptor were detected in both small and large intestine as well as in pancreas, liver, lung, and kidney. Both glucagon and GLP-1 receptor mRNA transcripts were identified in different regions of the fetal and adult mouse brain, but the relative levels of GLP-1 receptor mRNA transcripts were much greater in the central nervous system. Furthermore, regulation of the GLP-1 receptor (but not the glucagon receptor) gene in the brain resembled the pattern of region-specific gene expression recently defined for the mouse proglucagon gene. Taken together, these studies define novel sites for both glucagon and GLP-1 receptor gene expression in the mouse and suggest that different regulatory mechanisms have evolved for tissue-specific and developmental control of receptor gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8156917     DOI: 10.1210/endo.134.5.8156917

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  78 in total

1.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

2.  Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning.

Authors:  Yuriko Mori; Alexandru V Olaru; Yulan Cheng; Rachana Agarwal; Jian Yang; Delgermaa Luvsanjav; Wayne Yu; Florin M Selaru; Susan Hutfless; Mark Lazarev; John H Kwon; Steven R Brant; Michael R Marohn; David F Hutcheon; Mark D Duncan; Ajay Goel; Stephen J Meltzer
Journal:  Endocr Relat Cancer       Date:  2011-07-04       Impact factor: 5.678

3.  Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

Authors:  Sara Baldassano; Guo-Du Wang; Flavia Mulè; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-10       Impact factor: 4.052

Review 4.  Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.

Authors:  Paige V Bauer; Sophie C Hamr; Frank A Duca
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

Review 5.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

Review 6.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

7.  Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.

Authors:  Kristopher C Dozier; Elizabeth L Cureton; Rita O Kwan; Brian Curran; Javid Sadjadi; Gregory P Victorino
Journal:  Peptides       Date:  2009-06-26       Impact factor: 3.750

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

10.  High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.

Authors:  Joram D Mul; Denovan P Begg; Jason G Barrera; Bailing Li; Emily K Matter; David A D'Alessio; Stephen C Woods; Randy J Seeley; Darleen A Sandoval
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-24       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.